Jun 29, 2024, 11:05
Neoadjuvant botensilimab and balstilimab in colorectal cancer
Smitha Krishnamurthi, Gastrointestinal medical oncologist at Cleveland Clinic, shared on X:
“Neoadjuvant botensilimab (1 dose) and balstilimab (4 doses) resulted in pathologic complete response in 5/9 patients with pMMR colorectal cancer!
Early results but super impressive.”
Source: Smitha Krishnamurthi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12